Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin/Cyclophosphamide vs Docetaxel/Cyclophosphamide in Neoadjuvant Breast Cancer
NCT01527487Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jun 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eribulin in breast cancer (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Pathologic Complete Response Rate at 18 weeks. Started Jun 2012; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01527487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527487.